Of course though if FTT had indicated that the real reason why the EMA had knocked it back was because it had concerns about its efficacy (or in plainspeak, the EMA were concerned it didnt actually work) then there would have been a bit of a problem for the company raising funds for a clinical trial. Much easier to say to us - "hop on board. This is a derisked proven product"
Ann: Chairman's Address to AGM and Shareholder Presentation, page-6
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
